Claims

1. An inhibitor for IDO expression, comprising 3-ethyl-4-{3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl}benzamide or a salt thereof as an active ingredient.

2. The inhibitor for IDO expression according to claim 1, which is in a form comprising a pharmaceutically acceptable carrier.

3. A pharmaceutical composition for treating IDO-positive tumors, comprising 3-ethyl-4-{3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl}benzamide or a salt thereof as an active ingredient, characterized by inhibiting IDO expression.

4. A method for evaluating the effectiveness of chemotherapy comprising 3-ethyl-4-{3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl}benzamide or a salt thereof, the method comprising

a step of detecting an IDO protein or an IDO gene in a biological sample, and

a step of evaluating the chemotherapy comprising 3-ethyl-4-{3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl}benzamide or a salt thereof as being effective when the IDO protein and/or the IDO gene are/is detected in the biological sample.